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**Joannidis *et al.*** (*Intensive Care Med.* 2020;46:654--672. <https://doi.org/10.1007/s00134-019-05869-7>.)

Multi-organ dysfunction in critical illness is common. Patients with acute kidney injury (AKI) are twice as likely to require mechanical ventilation. Patients with acute respiratory failure/acute respiratory distress syndrome (ARF/ARDS) are at increased risk of AKI. The Acute Disease Quality Initiative (ADQI) held a consensus conference on the spectrum of lung--kidney interactions in critical illness in June 2018, well before the outbreak of coronavirus disease 2019 (COVID-19). Through review and critical appraisal of the available evidence, they described the current state of research and recommendations.

Incidences of respiratory failure are between 23% and 44% where renal replacement therapy (RRT) is initiated. To mitigate respiratory dysfunction among patients with AKI, appropriate timing of RRT initiation and the rate and volume of fluid and solute removal should be determined by patient characteristics and clinical circumstances. Incidences of AKI in patients with ARF/ARDS are between 25% and 60% in mechanically ventilated patients with ARF/ARDS with a consistent independent association between AKI and mortality. The pathophysiological mechanisms underlying the association between respiratory failure and AKI comprise inflammatory/immune-mediated effects. The effects of impaired gas exchange and hemodynamic disturbance including right heart failure may also contribute to the risk of AKI. They recommended daily measurement of serum creatinine and regular monitoring of urine output in patients with severe ARF/ARDS to detect development of AKI.

Patients with ARF/ARDS treated with extracorporeal membrane oxygenation (ECMO) are at increased risk of severe AKI. Development of AKI, as well as positive fluid balance in patients receiving ECMO, is associated with an increased mortality rate. It remains unclear whether ECMO itself contributes to AKI. The pathophysiological interactions between ECMO and AKI may include hemodynamic, inflammatory, and immune-mediated effects and hemolysis ([Figure 1](#fig1){ref-type="fig"} ). At this moment, there is no evidence that combinations of extracorporeal lung and renal support are of benefit.Figure 1**Possible effects of acute respiratory failure and invasive/noninvasive ventilation on renal function.** Reproduced from Joannidis M, Forni LG, Klein SJ, et al. Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. *Intensive Care Med*. 2020;46:654--672, under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>).

In conclusion, the ADQI 21 conference revealed significant knowledge gaps about organ crosstalk between lung and kidney and its relevance for critically ill patients. Lung-protective ventilation, conservative fluid management, and early recognition and treatment of pulmonary infections were the only clinical recommendations with higher quality of evidence. Our experiences with COVID-19 emphasized a critical role of crosstalk between lung and kidney. Research targeting lung--kidney interactions is mandatory.

**---Masaomi Nangaku**
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**Fernández-Ruiz *et al.*** (COVID-19 in solid organ transplant recipients: a single-center case series from Spain \[e-pub ahead of print\]. *Am J Transplant.* <https://doi.org/10.1111/ajt.15929>. Accessed May 21, 2020.)

There is lingering uncertainty of how best to deal with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections or COVID-19 in recipients of solid organ transplants. Colleagues from a large tertiary referral center in Madrid, Spain, report their early experience in 18 such patients with a polymerase chain reaction--confirmed COVID-19 diagnosis, of whom 8 had a kidney transplant, whereas the others had a liver (N = 6) or heart (N = 4) transplant. Average age was 71 years, 78% were men, and they had been transplanted for a median of 9 years. Initial symptoms included fever (N = 15), cough and dyspnea (N = 11), gastrointestinal symptoms (N = 5), in particular, diarrhea, and respiratory failure defined as oxygen saturation at room air below 91% (N = 5). Uni- or bilateral radiographic abnormalities were present in the initial chest X-ray in 13 of the patients, but computed tomography scans were not performed. Notable clinical features in single patients were isolated diarrhea as the only presentation and rapid pulmonary deterioration within 48 hours after an initial discharge from the hospital with mild symptoms and no evidence of pneumonia on the chest X-ray.

Half of the patients received co-formulated lopinavir/ritonavir and 72% hydroxychloroquine. Another 5% to 15% of the patients were treated with subcutaneous interferon-β, i.v. Ig, or tocilizumab. With respect to immunosuppression, 10 of 18 patients had their calcineurin inhibitor therapy paused or reduced, baseline daily prednisone dose was usually halved, and mycophenolate mofetil/mycophenolic acid was unchanged, discontinued (in 50%), or decreased. Tacrolimus trough levels were difficult to manage in those patients with the dual antiviral therapy. After a median period of 18 days after the onset of symptoms, 5 patients had died (28%), most of them men older than 60 years of age. Of the surviving 13 patients, 4 experienced progressive respiratory failure and/or acute respiratory distress syndrome (ARDS), 1 was in stable clinical condition, and 8 had been discharged from the hospital. There were no cases of acute graft rejection. A comparison of laboratory features of the 9 patients who died or who developed severe pulmonary disease with those who had a more benign course showed higher C-reactive protein levels and lower lymphocyte counts in the former, whereas demographic features did not differ.

Taken together, the above data show that in Madrid, one of the most intensely affected areas in Spain, a COVID-19 diagnosis carried a dismal prognosis in many solid organ recipients, consistent with a recent British report on kidney transplant recipients in this journal.[@bib1] The diversity of the therapeutic approaches precludes any firm conclusions on potential treatments. However, recommendations on how to adjust immunosuppressive medications more systematically have been published in the meantime, for example, by the DESCARTES working group of the European Renal Association (<https://www.era-edta.org/en/wp-content/uploads/2020/04/Expert-opinion-on-ISD-in-Covid-19.pdf>).

**---Jürgen Floege**
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**Battistone *et al.*** (*J Clin Invest*. <https://doi.org/10.1172/JCI134791>. Accessed May 1, 2020.)

The intercalated cell plays a major role in acid--base balance, potassium homeostasis, and salt and water reabsorption. A role in the innate immune system in response to bacteria has also been suggested. The current study shows that the intercalated cell also plays a key role in the early responses to ischemia. AKI commonly occurs because of ischemia, which results in release of danger-associated molecular pattern (DAMP) molecules. DAMP binding to pattern recognition receptors can then cause release of chemokines. The result is an influx of polymorphonuclear leukocytes and monocytes, which can further promote tissue injury and dysfunction. The current study investigated the role of uridine diphosphate glucose (UDP-Glc) and its binding to the P2Y14 receptor on the intercalated cell. The intercalated cell strongly expresses the P2Y14 receptor on the apical membrane. Binding of UDP-Glc to this receptor after injury was associated with an influx of inflammatory cells, proximal tubular injury, and renal dysfunction in the mouse ischemia/reperfusion model. The specific role of this P2Y14-UDP-Glc axis in injury was demonstrated by blocking the receptor, or specific ablation of this gene in intercalated cells ([Figure 2](#fig2){ref-type="fig"} ). These manipulations inhibited the increased chemokine expression in intercalated cells, decreased the inflammatory cell infiltrate, and importantly, led to less renal dysfunction and less proximal tubular damage after ischemia/reperfusion. Possible translational significance was shown by demonstrating that urine UDP-Glc concentration was higher in patients in the intensive care unit with AKI compared with those without AKI. These studies show a novel role for the UDP-glucose/P2Y14 receptor axis, particularly in the intercalated cell, as an early initiator and propellant of ischemia-induced AKI.Figure 2**Ischemic injury results in release of UDP-Glc from injured cells, which reaches the tubular lumen and binds to the P2Y124 receptor on intercalated cells (ICs).** These cells then produce proinflammatory cytokines (PICs), resulting in infiltration of inflammatory cells into the kidney parenchyma. These inflammatory cells further perpetuate injury. Used with permission of American Society for Clinical Investigation, from Battistone MA, Mendelsohn AC, Spallanzani RG, et al. Pro-inflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice. *J Clin Invest.*<https://doi.org/10.1172/JCI134791>. Copryright © 2020, permission conveyed through Copyright Clearance Center.

**---Agnes B. Fogo**
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**Gaudry *et al.*** (*The Lancet.* 2020;395:1506--1515. <https://doi.org/10.1016/S0140-6736(20)30531-6>.)

The timing of RRT in the setting of AKI is an ongoing debate. Gaudry *et al.* reported the results of an individual patient data meta-analysis using data from selected randomized clinical trials (RCT) published between 2008 and 2019. The primary outcome of choice was 28-day all-cause mortality. After careful selection, individual patient data were analyzed in 1879 patients (88% of the overall cohort): 946 in the delayed RRT group and 933 in the early RRT group. In patients in whom mortality at day 28 after randomization was available, there was no statistically significant difference between the delayed RRT group (366 \[44%\] of 837 patients) and the early RRT group (355 \[43%\] of 827; risk ratio 1.01 \[95% confidence interval, 0.91--1.13\]) ([Figure 3](#fig3){ref-type="fig"} ). The results of this individual patient data meta-analysis suggest that timing of RRT did not affect 28-day survival in critically ill patients with severe AKI. The data also showed no significant differences in number of subgroup analyses. The quality and scope of this analyses are obvious strengths of this important study. On the other hand, the criteria for initiation of RRT are not standardized in RCTs included in the analysis. This is especially applicable whether RRT is initiated because of metabolic abnormalities or fluid management. The observation that a significant number of patients (42%) in the delayed group did not start RRT at all suggests that the decision to initiate RRT is not always predictable and depends on the acute changes that are commonly observed in the intensive care unit setting. Nevertheless, it does provide an impetus for watchful waiting before starting RRT in patients with AKI without an obvious emergent need. Until the results from other ongoing RCTs are available to provide more answers to this conundrum, this study fills an important gap and supports a conservative overall approach to patients with severe AKI.Figure 3**Probability of survival up to day 28 in the intention-to-treat population according to RRT initiation strategy.** Reprinted with permission from Elsevier from *The Lancet*, Gaudry S, Hajage D, Benichou N, et al., Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomized clinical trials. 2020;395:1506--1515. Copyright © 2020 Elsevier Ltd. All rights reserved.

**---T. Alp Ikizler**
